HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin

• Published in: Journal of viral hepatitis 2000-11, Vol.7 (6), p.409-413
• Main Authors: Carlsson, T., Lindahl, K., Schvarcz, R., Wejstal, R., Uhnoo, I., Shev, S., Reichard, O.
• Format: Article
• Language: English
• Subjects: Adult; amantadine; Amantadine - therapeutic use; Antiviral Agents - therapeutic use; Chronic hepatitis C; Drug Therapy, Combination; Female; HCV RNA; Hepacivirus - isolation & purification; Hepacivirus - physiology; Hepatitis C virus; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - virology; Humans; interferon alpha; Interferon-alpha - therapeutic use; Male; Medicin och hälsovetenskap; Middle Aged; Pilot Projects; Recombinant Proteins; Recurrence; ribavirin; Ribavirin - therapeutic use; RNA, Viral - blood; treatment; Treatment Failure; Treatment Outcome
• ISSN: 1352-0504; 1365-2893
• DOI: 10.1046/j.1365-2893.2000.00256.x

Interferon (IFN) alpha in combination with ribavirin (RIB) is standard therapy for patients with chronic hepatitis C virus (HCV) infection. However, many patients do not respond with sustained HCV clearance to this therapy. At present, no accepted treatment strategy exists for these patients. Recent preliminary data have suggested that amantadine (AMA) is effective against HCV infection. In a pilot study, we treated 13 nonresponders and 10 response/relapsers to previous IFN/RIB therapy with AMA 200 mg per day in combination with IFN 3 MU thrice weekly, and RIB 1000 mg per day for 24 weeks, with a 24‐week follow‐up period after end‐of‐treatment. At the end‐of‐treatment, 1 previous nonresponder and 5 previous response/relapsers were HCV RNA negative. At the end of follow‐up, only 1 previous response/relapser remained HCV RNA negative and had a sustained response. During therapy, serum HCV RNA became undetectable in 4 previous nonresponders, of whom 3 had a breakthrough at week 24. Twenty‐one patients continued therapy without dose reductions. One patient discontinued therapy prematurely due to sleeping disturbances, and another patient was withdrawn from therapy due to heavy alcohol intake. We conclude that the addition of AMA to IFN and RIB was well tolerated but had little, if any, impact on HCV RNA eradication in nonresponders or response/relapsers to previous IFN/RIB combination therapy.